FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Markvicka Taunia						2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [ PCRX ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
(Last)	`	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/14/2013									X below	r (give title r) e Presiden	ıt, Co	below)	specify	
C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 100						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	PANY N	J (	07054												X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate) (	Zip)													n				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				· ·	Exe if ar	ıy	med on Date, Day/Year	3. Transac Code (I		4. Securities Acquired Disposed Of (D) (Instr. and 5)				Securit Benefic Owned	ies cially	Forr (D) o Indi	m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amoun	t (A) or (D)		Price			(Instr. 4)		(Instr. 4)	
Common Stock 08/14/.					2013	013			М		14,70	14,700 A		\$1.6	1 14	1,700		D		
Common Stock 08			08/14/	2013		S <sup>(1)</sup>		14,700		D	\$37		0		D					
		Ta	able II						uired, D , option						/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed on Date, Day/Year)	4. Transaction Code (Instr. B)				6. Date Exercisable an Expiration Date (Month/Day/Year)			d 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	or Nu of	umber						
Employee Stock Option (right to buy)	\$1.61	08/14/2013			M			14,700	(2)	0	9/01/2020	Comme Stock		4,700	\$0	6,685		D		

## Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. The stock option vests as follows: 25% of the options vested on September 2, 2011; the remaining options vest in successive equal monthly installments over the subsequent 36 months.

/s/ James Scibetta, attorney-infact 08/16/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.